Avanos Medical Inc. (AVNS)
15.10
0.05 (0.33%)
At close: Mar 03, 2025, 3:59 PM
15.13
0.20%
After-hours: Mar 03, 2025, 04:55 PM EST
Avanos Medical Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Digestive Health Revenue | 98.2M | 97.7M | 94.7M | 183.6M | 95M | 93M | 35.8M | 47.4M | 47.5M | 49.5M | 39.3M |
| Digestive Health Revenue Growth | +0.51% | +3.17% | -48.42% | +93.26% | +2.15% | +159.78% | -24.47% | -0.21% | -4.04% | +25.95% | n/a |
| Interventional pain Revenue | 41.9M | 41.7M | 40.2M | n/a | 42.2M | 41.6M | n/a | n/a | n/a | n/a | n/a |
| Interventional pain Revenue Growth | +0.48% | +3.73% | n/a | n/a | +1.44% | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States Revenue | 467M | 560.7M | 521.6M | 482M | 481M | 457M | 467M | 1.1B | 1.1B | 1.1B |
| United States Revenue Growth | -16.71% | +7.50% | +8.22% | +0.21% | +5.25% | -2.14% | -57.55% | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 74.3M | 73.2M | 80.4M | 68.4M | 78.7M | 93M | 92.7M | 82.6M | 82.1M | 87.1M | 90.1M | 75.2M | 75M | 76.7M | 73.4M | 82.2M | 82.4M | 76.9M | 91.1M | 103.6M | 94.4M | 94.7M | 106.4M | 87.9M | 86.3M | 79.8M | 86.4M | 19.2M | 101.2M | 100.1M | 101.2M | 110.1M | 100.3M | 107.9M | 92.8M | 98.3M | 97.2M | 105.8M | 97.2M |
| Selling, General, and Administrative Revenue Growth | +1.50% | -8.96% | +17.54% | -13.09% | -15.38% | +0.32% | +12.23% | +0.61% | -5.74% | -3.33% | +19.81% | +0.27% | -2.22% | +4.50% | -10.71% | -0.24% | +7.15% | -15.59% | -12.07% | +9.75% | -0.32% | -11.00% | +21.05% | +1.85% | +8.15% | -7.64% | +350.00% | -81.03% | +1.10% | -1.09% | -8.08% | +9.77% | -7.04% | +16.27% | -5.60% | +1.13% | -8.13% | +8.85% | n/a |
| Research and Development Revenue | 7.2M | 6.3M | 7M | 6.8M | 6.1M | 6.8M | 7.9M | 7.5M | 7.3M | 8M | 7.8M | 7.6M | 8.4M | 8M | 8.3M | 9.6M | 8.2M | 7.7M | 9.4M | 8.4M | 9.6M | 9.5M | 10.2M | 10.6M | 10.5M | 10.8M | 9.9M | 10.1M | 10.3M | 9.8M | 8M | 12M | 10.9M | 9.5M | 8.7M | 9.8M | 10.2M | 6.3M | 6M |
| Research and Development Revenue Growth | +14.29% | -10.00% | +2.94% | +11.48% | -10.29% | -13.92% | +5.33% | +2.74% | -8.75% | +2.56% | +2.63% | -9.52% | +5.00% | -3.61% | -13.54% | +17.07% | +6.49% | -18.09% | +11.90% | -12.50% | +1.05% | -6.86% | -3.77% | +0.95% | -2.78% | +9.09% | -1.98% | -1.94% | +5.10% | +22.50% | -33.33% | +10.09% | +14.74% | +9.20% | -11.22% | -3.92% | +61.90% | +5.00% | n/a |